Samuel Kintz Sells 526 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 526 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $27.54, for a total value of $14,486.04. Following the completion of the transaction, the chief executive officer now directly owns 1,048,729 shares in the company, valued at $28,881,996.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.89, for a total value of $274,680.00.
• On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.56, for a total value of $62,561.20.
• On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.92, for a total value of $299,040.00.

Enliven Therapeutics Stock Performance

Shares of ELVN stock opened at $27.53 on Friday. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $27.67. The company has a market cap of $1.29 billion, a PE ratio of -14.26 and a beta of 1.09. The stock’s fifty day moving average price is $23.21 and its two-hundred day moving average price is $21.97.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.17. On average, equities analysts predict that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ELVN. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday. Robert W. Baird started coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 target price on the stock. Finally, Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. China Universal Asset Management Co. Ltd. increased its holdings in shares of Enliven Therapeutics by 67.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after buying an additional 3,189 shares in the last quarter. EntryPoint Capital LLC bought a new stake in shares of Enliven Therapeutics during the first quarter worth about $167,000. Baker BROS. Advisors LP acquired a new stake in Enliven Therapeutics during the 1st quarter worth approximately $2,020,000. Blackstone Inc. bought a new stake in Enliven Therapeutics during the 1st quarter worth approximately $443,000. Finally, Janus Henderson Group PLC increased its position in Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after acquiring an additional 305,397 shares during the period. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.